Onconetix Shareholders Approve Flexible Reverse Stock Split Plan

Onconetix ( (ONCO) ) has issued an announcement.

On February 3, 2026, Onconetic, Inc. held a special meeting of stockholders to vote on a reverse stock split of its common stock, authorizing the board to implement a split ratio between 1-for-2 and 1-for-50 at any time within one year of the meeting. Shareholders also considered a proposal to allow adjournment of the meeting if additional proxies were needed, with both measures approved based on 1,555,015 shares outstanding as of the December 12, 2025 record date.

The reverse stock split proposal passed with 562,803 votes in favor, 123,144 against and 986 abstentions, giving the board significant flexibility to manage the company’s share price and compliance considerations going forward. The adjournment proposal was also approved, with 567,357 votes for, 118,604 against and 972 abstentions, reinforcing stockholder support for the board’s discretion in handling future procedural needs tied to these capital structure changes.

Spark’s Take on ONCO Stock

According to Spark, TipRanks’ AI Analyst, ONCO is a Underperform.

Onconetix’s overall score reflects substantial financial difficulties with significant operating losses and negative profitability metrics. The technical analysis suggests a bearish trend, and the valuation metrics are unfavorable due to negative earnings. These factors combine to give the stock a low attractiveness score.

To see Spark’s full report on ONCO stock, click here.

More about Onconetix

Onconetic, Inc. is a publicly traded company in the healthcare sector, focused on developing oncology-related products and technologies. The company’s common stock trades on the public markets, and its capital structure and share count are key considerations for its stockholders and corporate governance activities.

Average Trading Volume: 77,012

Technical Sentiment Signal: Sell

Current Market Cap: $1.82M

For a thorough assessment of ONCO stock, go to TipRanks’ Stock Analysis page.